BioSpace News Archive

New research from Propeller Health, the University of Wisconsin-Madison and the University of California, Berkeley, is the first nationwide study to show an association between daily air pollution and rescue inhaler use using data obtained objectively from digital medicines.

The CARIN Alliance, a multi-sector group of health care and other stakeholders, has developed a voluntary code of conduct for entities not covered by HIPAA, such as third-party applications, when handling health care data accessed via application programming interfaces (APIs)

The fall fundraising efforts are a continuation of the company’s longstanding partnership with BCRF to fund life-changing research and eradicate breast cancer.

Spherix Incorporated (Nasdaq: SPEX) today announced the funding of a study for KPC34, for pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDA).

Support Now Available to Assist with Copayments and Premiums

Frazier Healthcare Partners announced Mimi Hancock, Ph.D. has joined its Life Sciences team as a Senior Advisor to assist with attracting top talent for Frazier companies.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that data from the Phase 1 MoveDMD clinical trial of edasalonexent were published in the Journal of Neuromuscular Diseases, “Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-kB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy”.

The Bridging Clinical Research & Clinical Health Care Collaborative, a forum where health care professionals, patients, physicians, academics, clinical researchers, service and technology providers, and regulatory authorities convene to advance clinical research and its integration with health care, has released a preliminary list of its 2019 agenda topics.

MedX Health Corp. (“MedX”) (TSX-V: MDX) announces that it has signed a Memorandum of Understanding with a consortium of Dutch companies that will be launching an easy-access skin scanning/assessment program in the Netherlands, using MedX’s SIAscopy and DermSecureTM technologies.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company will present new data highlighting the potential of rezafungin to prevent invasive fungal infections in bone marrow transplantation (BMT) patients at the 60th American Society of Hematology (ASH) Annual Meeting.